Cancer Drug Resistance Achieves CiteScore 2025 of 10.3 and Advances to Q1 in Cancer Research
Cancer Drug Resistance (CDR) is pleased to announce a significant milestone in its continued growth and international impact. According to the newly released CiteScore 2025 metrics from Elsevier, the journal's CiteScore has increased from 8.3 to 10.3, representing a 24% year-over-year increase.
The latest performance reflects the growing visibility, influence, and citation impact of research published in CDR across the global oncology and biomedical research communities.
Strong Performance Across Multiple Disciplines
In the 2025 CiteScore rankings, CDR continues to strengthen its position among leading journals in both pharmacology and cancer research.
Medicine: Pharmacology (medical)
- Ranked 20th out of 278 journals
- Positioned within the top 8% worldwide
- Maintains its status in Q1
Biochemistry, Genetics and Molecular Biology: Cancer Research
- Advanced from Q2 to Q1
- Now ranked within the top 20% of journals in the field
This advancement highlights the journal's increasing recognition among researchers working at the interface of cancer biology, translational oncology, drug development, and therapeutic resistance.
Reflecting Growing Impact in Cancer Drug Resistance Research
The continued rise in CiteScore underscores the relevance and quality of the research being published in CDR. As cancer drug resistance remains one of the most pressing challenges in oncology, the journal has established itself as a dedicated platform for disseminating discoveries that advance our understanding of resistance mechanisms and support the development of more effective therapeutic strategies.
Over recent years, CDR has expanded its global reach while maintaining a strong commitment to rigorous peer review, scientific excellence, and rapid dissemination of high-quality research. The journal's growing citation performance reflects the increasing engagement of the international research community with the work published in its pages.
Looking Ahead
Since its launch in 2018, Cancer Drug Resistance has focused on publishing innovative research spanning molecular mechanisms of resistance, precision oncology, liquid biopsy, immunotherapy resistance, targeted therapies, tumor evolution, and emerging approaches to overcoming treatment failure.
The journal remains committed to providing an open-access platform that supports scientific exchange and accelerates progress in cancer research worldwide. Building on this latest achievement, CDR will continue to attract impactful submissions, strengthen its international presence, and serve as a trusted venue for researchers dedicated to improving outcomes for patients with cancer.
Acknowledgement
These achievements would not have been possible without the invaluable contributions of our authors, reviewers, Editorial Board members, Early Career Editorial Board members, guest editors, and readers around the world.
We sincerely thank our community for its continued support and look forward to advancing the field of cancer drug resistance together.
Editor: Louise Pan
Language Editor: Amir Khan
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Cancer Drug Resistance
